Resistance to Targeted Therapies in Breast Cancer / edited by Jenifer R. Prosperi

Mitwirkende(r):

Prosperi, Jenifer R [HerausgeberIn]

Resource type: Ressourcentyp: Buch (Online)Buch (Online)Sprache: Englisch Reihen: Resistance to Targeted Anti-Cancer Therapeutics ; 16 | SpringerLink Bücher | Springer eBook Collection Biomedical and Life SciencesVerlag: Cham : Springer, 2017Beschreibung: Online-Ressource (XV, 184 p. 12 illus. in color, online resource)ISBN:

9783319701424

Schlagwörter:

Andere physische Formen: 9783319701417 | Erscheint auch als: 978-3-319-70141-7 Druck-Ausgabe | Printed edition: 9783319701417 LOC-Klassifikation:

RC261-271

NLM-Klassifikation:

WP 870

DOI: DOI: 10.1007/978-3-319-70142-4Online-Ressourcen:

Zusammenfassung: We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.Zusammenfassung: Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatmentPPN: PPN: 1658624858Package identifier: Produktsigel: ZDB-2-SBL

Exemplare ( 0 )

Dieser Titel hat keine Exemplare